Insider Shareholders with Direct Ownership of An2 Therapeutics, Inc. (ANTX)
This section provides a comprehensive overview of the insiders with direct ownership of An2 Therapeutics, Inc. (ANTX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
AN2 Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 0 | 214,777 | 2,184,224 $2.49 Million | 11 |
Jun 06, 2022
Reduced 1.2%
|
|
|
Eric Easom
Chief Executive Officer |
259,157 | 97,008 | 256,380 $292,273 | 21 |
Jun 02, 2025
Added 3.75%
|
| 180,000 | 37,336 | 152,499 $173,848 | 8 |
Jan 06, 2026
Reduced 4.35%
|
|
| 145,538 | 0 | 145,538 $165,913 | 6 |
Apr 10, 2025
Added 6.74%
|
|
|
Sanjay Chanda
Chief Development Officer |
77,750 | 12,208 | 75,823 $86,438 | 5 |
Jan 06, 2026
Reduced 7.28%
|
|
Lucy Day
Chief Financial Officer |
74,000 | 11,764 | 75,363 $85,913 | 5 |
Jan 06, 2026
Reduced 6.82%
|
| 52,479 | 0 | 75,309 $85,852 | 5 |
Jan 12, 2026
Added 13.31%
|
|
|
Stephen David Prior
Chief Strategy Officer |
38,125 | 9,256 | 59,086 $67,358 | 6 |
Jan 06, 2026
Reduced 4.61%
|
| 52,479 | 0 | 52,479 $59,826 | 5 |
Jan 12, 2026
Added 18.05%
|
|
|
Paul Eckburg
Chief Medical Officer |
30,000 | 0 | 51,416 $58,614 | 1 |
Mar 15, 2024
Added 36.85%
|
|
Kevin Michael Krause
Chief Strategy Officer |
40,000 | 10,000 | 31,914 $36,381 | 5 |
Mar 15, 2024
Added 48.45%
|
| 16,905 | 0 | 16,905 $19,271 | 5 |
Jan 12, 2026
Added 17.76%
|
|
| 9,077 | 0 | 9,077 $10,347 | 1 |
Dec 19, 2024
Added 50.0%
|
|
| 8,610 | 0 | 8,610 $9,815 | 1 |
May 28, 2025
Added 50.0%
|
|